---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-096103"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2025-10-02T23:59:59+00:00"
generated_at: "2026-05-17T04:55:58.631628+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# David Moore joins Corvus board as Class III director through 2028; gets 30K option grant

## Summary
- David Moore appointed as Class III director, term expires at 2028 annual meeting.
- Moore will serve on Compensation Committee ($6K/yr) and Nominating Committee ($4K/yr).
- Receives $35K annual retainer and initial option to purchase 30,000 shares of common stock.
- Appointment effective October 2, 2025.

## SEC filing metadata
- accession: 0001104659-25-096103
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2025-10-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000110465925096103/0001104659-25-096103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000110465925096103/crvs-20251002x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-096103
- JSON: https://secwatch.observer/filing/0001104659-25-096103.json
- Plain text: https://secwatch.observer/filing/0001104659-25-096103.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.